Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions Inc (NASDAQ: BLFS) maintains industry leadership through innovative biopreservation solutions for cell and gene therapies. This dedicated news hub provides comprehensive updates on corporate developments, regulatory milestones, and technological advancements essential for stakeholders in the life sciences sector.
Access official press releases covering quarterly earnings, strategic partnerships, and product innovations in cryopreservation media and cold chain management systems. Our curated collection serves investors and researchers requiring timely, accurate information about BLFS's role in advancing biologic manufacturing infrastructure.
The resource prioritizes updates on BioLife's core competencies: clinical-grade cell processing tools, smart shipper technologies, and quality assurance protocols critical for therapy commercialization. Content spans regulatory filings, manufacturing expansions, and intellectual property developments shaping the biostorage industry.
For consistent monitoring of BioLife's market position, bookmark this page or subscribe to Stock Titan's update alerts. All materials maintain strict editorial standards to support informed decision-making in the rapidly evolving cell therapy landscape.
BioLife Solutions (BLFS) reported a record second quarter 2021 revenue of $31.2 million, reflecting a 215% year-over-year increase. The growth was fueled by acquisitions, including Stirling Ultracold, contributing $13.3 million. Adjusted net income was $422,000 for the six months ending June 30, while earnings per diluted share rose to $0.19. The company also updated its 2021 revenue guidance to between $108 million and $117 million, showing continued confidence in their market position.
On August 9, 2021, BioLife Solutions (NASDAQ: BLFS) announced its agreement to acquire Sexton Biotechnologies for a total deal value of $30 million. This acquisition aims to enhance BioLife's capabilities in the cell and gene therapy sector by integrating Sexton's innovative technologies such as CellSeal cryogenic storage vials and the Signata CT-5 fluid handling system. The merger is expected to strengthen BioLife's product offerings and relationships with cell and gene therapy developers, positioning the combined organization for further growth.
BioLife Solutions (Nasdaq: BLFS) has announced its acquisition of Sexton Biotechnologies for $24.0 million, paid through 506,382 newly issued shares. This transaction is expected to close by September 1, 2021. Sexton's products, including closed vials and human platelet lysate media, are integral to over 50 clinical trials. The acquisition is projected to contribute approximately $2 million to BioLife's 2021 revenue and $8 million in 2022, benefiting from synergies between both companies' offerings.
BioLife Solutions (NASDAQ: BLFS) will release its second quarter 2021 financial results on August 12, 2021, after market close. A conference call and live webcast will follow at 4:30 p.m. ET. The call will provide insights into the financial results and an overall business update. Investors can access the webcast on BioLife's Investor Relations page or join the call using Conference ID: 8083954. BioLife is known for its innovative bioproduction products tailored for cell and gene therapies.
BioLife Solutions (Nasdaq: BLFS) has announced changes to its board of directors, effective July 12, 2021. Raymond W. Cohen resigned from the board after serving since 2006 and as chairman since 2013. Mike Rice, the current CEO, has been appointed as the new chairman. Cohen expressed gratitude for his time at BioLife, highlighting the company's growth in bioproduction tools for cell and gene therapies. The leadership transition aims to ensure continued strategic direction and growth.
BioLife Solutions (Nasdaq: BLFS) announced a new corporate brand identity, including a redesigned logo and website, aimed at better representing its expanded portfolio of bioproduction products for cell and gene therapies. The new branding reflects BioLife's mission as a leader in biopreservation tools and is designed for flexibility in digital environments. Key features of the updated website include enhanced e-commerce capabilities, a broader product catalog, improved security, and integration of previously acquired companies.
BioLife Solutions (Nasdaq: BLFS) announced the promotion of Caitlin Rice to Global Vice President, Customer Service, effective May 19, 2021. Reporting to President Dusty Tenney, Rice aims to enhance customer service initiatives supporting the evo® cold chain management system. Her prior experience as Senior Director for Commercial Support contributed to robust customer service programs. Caitlin holds degrees in public policy and law, enhancing her qualifications for this leadership role. This strategic move is expected to strengthen BioLife's position in the bioproduction sector.
BioLife Solutions (BLFS) reported record first-quarter revenue of $16.8 million, a 39% increase from $12.2 million year-over-year. The company gained 80 new customers, including 16 for its biopreservation media. The acquisition of Global Cooling Inc. is expected to contribute $40 million to $42 million to 2021 revenue, increasing overall guidance to between $106 million and $115 million. However, the company posted an operating loss of $981,000 and a net loss of $1.1 million.
BioLife Solutions (NASDAQ: BLFS) will release its Q1 2021 financial results on May 13, 2021, after market close. Following this, a conference call and live webcast will be held at 4:30 p.m. ET for an overview of the financial results and a business update. Interested parties can access the webcast on the company’s Investor Relations page or via conference call. The company specializes in bioproduction products for cell and gene therapies and the broader biopharma market.
BioLife Solutions (BLFS) has completed the acquisition of Stirling Ultracold, issuing 6,646,870 shares for 100% of Stirling's outstanding shares. Expected revenue contribution from Stirling for 2021 is $35 million to $37 million, contributing to BioLife's total projected revenue of $101 million to $110 million. Stirling will supply 100 ultra-low temperature freezers to a leading CDMO, expanding their partnership. CEO Mike Rice anticipates cross-selling opportunities with BioLife's bioproduction tools, enhancing market reach in cell and gene therapies.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
